Beta Bionics plans to announce Q2 2025 financial results on July 29, followed by a conference call.
Quiver AI Summary
Beta Bionics, Inc. has announced that it will release its financial results for the second quarter of 2025 after the markets close on July 29, 2025. Following the release, company management will host a conference call and webcast at 4:30 PM Eastern Time. Investors can access the webcast through the company's website and can find dial-in information for the call through a provided registration link. Beta Bionics focuses on developing innovative diabetes management solutions, notably the iLet Bionic Pancreas, which is the first FDA-cleared device that autonomously determines insulin doses, aiming to improve health outcomes for individuals requiring insulin.
Potential Positives
- Beta Bionics is reporting its upcoming financial results, indicating transparency and a commitment to keeping investors informed.
- The company highlights its innovative iLet Bionic Pancreas, the first FDA-cleared insulin delivery device, emphasizing its leadership in advancing diabetes management technology.
- The scheduled conference call and webcast provide an opportunity for investors to engage directly with management, enhancing shareholder communication.
- The press release positions Beta Bionics as a pioneer in the diabetes management sector, potentially attracting further interest from investors and partners seeking innovation in healthcare solutions.
Potential Negatives
- None
FAQ
When will Beta Bionics release its Q2 2025 financial results?
Beta Bionics plans to release its Q2 2025 financial results on July 29, 2025, after market close.
What time is the conference call for the financial results?
The conference call will be held at 4:30 pm Eastern Time (1:30 pm Pacific Time) on July 29, 2025.
How can I access the webcast of the conference call?
The webcast will be available on the Beta Bionics website in the “Investors—Events & Presentations” section.
What is the iLet Bionic Pancreas?
The iLet Bionic Pancreas is an FDA-cleared insulin delivery device that autonomously determines insulin doses for diabetes management.
Who should I contact for investor or media inquiries?
For investor inquiries, contact Blake Beber at [email protected]; for media inquiries, contact Karen Hynes at [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BBNX Insider Trading Activity
$BBNX insiders have traded $BBNX stock on the open market 18 times in the past 6 months. Of those trades, 2 have been purchases and 16 have been sales.
Here’s a breakdown of recent trading of $BBNX stock by insiders over the last 6 months:
- HADLEY HARBOR AGGREGATOR IV, L.P. WELLINGTON purchased 1,000,000 shares for an estimated $17,000,000
- MIKE MENSINGER (Chief Product Officer) has made 1 purchase buying 33,350 shares for an estimated $566,950 and 4 sales selling 1,128 shares for an estimated $20,168.
- SEAN SAINT (President & CEO) has made 0 purchases and 3 sales selling 3,439 shares for an estimated $61,525.
- STEPHEN FEIDER (Chief Financial Officer) has made 0 purchases and 3 sales selling 1,497 shares for an estimated $26,783.
- STEVEN JON RUSSELL (Chief Medical Officer) has made 0 purchases and 3 sales selling 1,039 shares for an estimated $18,588.
- MARK HOPMAN (Chief Commercial Officer) has made 0 purchases and 3 sales selling 868 shares for an estimated $15,529.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Full Release
IRVINE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its second quarter 2025 financial results after the financial markets close on Tuesday, July 29, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time).
The link to the webcast will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com , and will be archived there for future replay. To access the live call by phone, please use the following link, which will provide you with dial-in details and a personal pin: https://register-conf.media-server.com/register/BIc649100069fd4629a4ed5bf4826b8acb .
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com .
Investor Relations:
Blake Beber
Head of Investor Relations
[email protected]
Media and Public Relations
:
Karen Hynes
Vice President of Marketing
[email protected]
Source: Beta Bionics, Inc.
